Brink Therapeutics is a venture-backed biotech company specializing in the development of cutting-edge gene therapy tools. We focus on site-specific recombinases, highly efficient enzymes that enable precise DNA modifications - such as inserting, removing, or inverting DNA sequences - without causing double-strand breaks. These recombinases offer a safer, more precise alternative to existing technologies like CRISPR-Cas9, giving them the potential to revolutionize Cell and Gene Therapies and finally push them over the brink of mass accessibility.
By joining Brink Therapeutics, you will become part of a passionate and growing team at an exciting inflection point - with meaningful progress behind us and significant momentum ahead as we advance toward our Series A. Together, we are building an ambitious company harnessing advanced Directed Evolution, deep ...